Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys

Journal of Infection(2023)10.1016/j.jinf.2023.10.008Source: DataRank Database

Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys is a research paper published in Journal of Infection (2023). On theSindex it has a DataRank of 0. It has been cited 14 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access14 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (1 grants)Impact (FWCI 2.34)OA: hybridTopics (65)IDs (PubMed, OpenAlex)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (26)

Priscilla Turelli ORCID,Yoan Duhoo ORCID,Kelvin Lau ORCID,Cécile Hérate ORCID,Romain Marlin ORCID

Live enrichment

PubMed:37852477 OpenAlex:https://openalex.org/W4387675762

European Commission

Grant: 101005077

Corona Accelerated R&D in Europe

FWCI

2.34

Citation Percentile

0.9%

Citation Trend

2023

2024

2025

2026

hybridLicense: cc-by

journalhttp://www.journalofinfection.com/article/S016344532300539X/pdf

publisherhttp://www.journalofinfection.com/article/S016344532300539X/pdf

publisherhttps://api.elsevier.com/content/article/PII:S016344532300539X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S016344532300539X?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jinf.2023.10.008

Fields of Study

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesCOVID-19 Clinical Research Studies0301 basic medicine03 medical and health sciencesHumansAngiotensin-Converting Enzyme 2Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCOVID-19EpitopesSARS-CoV-2Spike Glycoprotein, CoronavirusAnimalsHaplorhiniSARS-CoV-2 variants

MeSH Terms

Angiotensin-Converting Enzyme 2COVID-19SARS-CoV-2AnimalsHaplorhiniAntibodies, MonoclonalAntibodies, ViralEpitopesHumansAntibodies, NeutralizingSpike Glycoprotein, Coronavirus

Keywords

EpitopeMonoclonal antibodyVirologyAntibodyNeutralizationInfectivityNeutralizing antibodyBiologyIn vivoVirusImmunologyGeneticsNeutralizing AntibodiesSars-cov-2Variants Of ConcernOmicronAce2 Mimetic[SDV.IMM] Life Sciences [q-bio]/ImmunologyAntibodies, ViralMicrobiologyEpitopesCRYO-EM STRUCTUREHumansAnimalsScience & Technology3202 Clinical sciencesAntibodies, MonoclonalCOVID-191103 Clinical SciencesACE2 mimetic; Neutralizing antibodies; Omicron; SARS-CoV-2; Variants of concern.HaplorhiniAntibodies, NeutralizingInfectious DiseasesSpike Glycoprotein, Coronavirus[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesAngiotensin-Converting Enzyme 2Life Sciences & Biomedicine

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being